8-K: SS Innovations Presents November 2025 Investor Update

SS Innovations International, Inc. furnished an updated November 2025 Company Presentation highlighting its advanced surgical robotic system, global expansion, and strong financial growth.

Summary

• SS Innovations International, Inc. (SSII) develops advanced, affordable, and accessible surgical robotic solutions, primarily its proprietary SSi Mantra 3 system.
• The company has installed 127 SSi Mantra systems in 120 hospitals across 8 countries as of September 30, 2025.
• Over 6,000 multi-specialty surgeries, including 319 robotic cardiac surgeries and 56 telesurgeries, have been performed using the SSi Mantra.
• Revenue for the nine months ended September 30, 2025, was $27.95 million, a 123% increase from $12.53 million in the same period of 2024.
• Gross margin improved to 47.1% for 9M 2025, up from 35.8% for 9M 2024.
• The company is expanding globally, with regulatory approvals in progress for Europe (CE Mark H1 2026) and the US (FDA Market Clearance H1 2026).
• SSII emphasizes its cost-effective platform, multi-specialty capabilities, and pioneering telesurgery, including the world's first intercontinental robotic cardiac telesurgery.

Sentiment

Score: 8

Explanation: The filing presents strong growth in revenue, gross margin, and system adoption, alongside significant global expansion plans and technological differentiation. While still operating at a net loss, the improvements are substantial and indicate positive momentum in a high-growth market.

Positives

• Strong revenue growth: +123% for 9M 2025 ($27.95 million) compared to 9M 2024 ($12.53 million).
• Significant gross margin improvement: 47.1% for 9M 2025, up from 35.8% for 9M 2024.
• Rapid adoption of SSi Mantra 3: Cumulative installed base grew from 43 systems (9/30/24) to 127 systems (9/30/25), a 195% increase.
• High volume of procedures: Over 6,000 multi-specialty surgeries performed to date, with 319 robotic cardiac surgeries.
• Pioneering robotic cardiac surgery: Actively advocating for this untapped market, performing complex procedures including beating heart TECAB.
• Global expansion underway with anticipated EU CE Mark and US FDA Market Clearance in H1 2026.
• Proprietary technology: SSi Mantra 3, comprehensive surgical instruments (SSi Mudra), and AI/XR-driven imaging/training (SSi Maya).
• Cost-effectiveness: Approximately 1/3rd the cost of competing systems, enhancing accessibility.
• Distinguished leadership: Includes Dr. Sudhir Srivastava (Founder, Chairman & CEO) and Dr. Frederic Moll (Vice-Chairman, Founder of Intuitive Surgical).

Negatives

• Net loss for 9M 2025 was $(9.66) million, although an improvement from $(17.23) million in 9M 2024.
• Operating loss for 9M 2025 was $(7.46) million, an improvement from $(17.14) million in 9M 2024.
• Diluted EPS remains negative at $(0.05) for 9M 2025.
• High insider ownership (76.5% as of 4/14/25) could limit public float.

Risks

• Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different.
• Actual events or results may differ materially from expectations due to factors beyond the company's control.
• Statistical and other industry and market data, including estimates of potential market opportunities, involve a number of assumptions and limitations and may not accurately reflect market opportunities.
• Access to robotic surgery remains limited globally due to high cost of acquisition and implementation, unattractive economics for hospitals with lower volumes, absence of trained personnel, and lack of versatility and adaptability of existing systems.

Future Outlook

SS Innovations aims to continuously improve and innovate its robotics platform, maintain its stronghold in India, grow in select underserved countries, and pursue established markets like Europe and the United States. The company anticipates EU CE Marking and US FDA Market Clearance in H1 2026, and expects the percentage of total revenue from the rest of the world to significantly expand from 8% in 2024. The global surgical robotics market is projected to reach $16.8 billion by 2031, with robotic surgeries growing fourfold by 2030.

Management Comments

• "Our Vision: To continuously improve and deploy our technologically-advanced, cost-effective surgical robotic systems, while maintaining affordability and accessibility for the benefit of a larger segment of patients globally."
• "SSII aims to accelerate access to surgical robotics in underserved regions of the world."
• "In October 2025, the first telesurgery performed with the SSi Mantra Tele Surgeon Console was successfully completed by Dr. Sudhir Srivastava at his residence in New Delhi, India."

Industry Context

The global surgical robotics market is large and growing, projected to reach $16.8 billion by 2031. Despite this growth, access to robotic surgery remains limited, with less than 1% of procedures performed robotically worldwide, largely due to high costs and lack of trained personnel. SSII positions itself to address these unmet needs, particularly in underserved regions like India, by offering a cost-effective, multi-specialty system with advanced features like telesurgery and AI/XR-driven training. The aging global population and increasing incidence of chronic diseases are driving the need for more surgical interventions, creating favorable industry tailwinds for companies like SSII.

Comparison to Industry Standards

• SSII's SSi Mantra 3 is approximately 1/3rd the cost of competing systems, enhancing affordability and accessibility.
• The SSi Mantra 3 features an ergonomic open-faced console, large 3D 4K monitor, large 2D touch controls monitor, hand and foot controls visibility, instant operating room visibility, and lightweight magnetic ergonomic controls, differentiating it from many competitors like Distalmotion, Microport, CMR, Medtronic, and Intuitive.
• SSII is the only company actively advocating for robotic cardiac surgery, including beating heart TECAB with its SSi stabilizer, addressing an untapped market potential.
• The SSi Mantra 3 offers a 5-arm system and flexible robotic arm configurations (3, 4, or 5 arms), providing versatility for various surgical needs.
• SSII's system is approved for telesurgery, enabling true remote access surgery, a capability not universally available or highlighted by all competitors.
• The SSi Mudra instruments have a 10-use life cycle per instrument, potentially offering cost advantages over single-use alternatives.

Stakeholder Impact

• Shareholders: Potential for increased value due to strong growth, global expansion, and market differentiation, but also continued operating losses.
• Patients: Improved access to advanced, affordable, and accessible surgical robotic systems, potentially leading to reduced trauma, shorter recovery times, and enhanced outcomes.
• Surgeons: Benefit from ergonomic systems that reduce fatigue, enhanced training pathways, and capabilities for complex procedures like robotic cardiac surgery and telesurgery.
• Hospitals/Providers: Potential for improved resource utilization, increased revenue, and reduced costs with lower complication rates and shorter lengths of stay.
• Employees: Growth and global expansion could lead to increased opportunities and job security.

Next Steps

• Continuously improve and innovate the SSi Mantra 3 platform through new product development and enhanced technology.
• Maintain stronghold in India and grow in select underserved countries with low penetration and cost barriers.
• Pursue established markets, specifically Europe and the United States.
• Focus on large multi-specialty hospitals for initial placements and expand the number of physicians using Mantra 3.
• Increase system utilization and place additional systems at existing hospitals.
• Target leading surgeons and thought leaders to raise awareness and encourage widespread adoption through advisory boards, medical conferences, and training programs.
• Achieve EU CE Marking in H1 2026.
• Achieve US FDA Market Clearance in H1 2026.
• Anticipate regulatory approvals in Colombia, Thailand (2025), Australia (TGA), Vietnam, Morocco, Brunei, Laos, and Nigeria (2026).

Key Dates

Recommendation

The company demonstrates robust growth in revenue and installed base, coupled with significant improvements in gross margin. Its strategic focus on cost-effective, multi-specialty robotic systems, particularly in underserved markets and pioneering areas like robotic cardiac surgery and telesurgery, positions it for substantial future expansion. Upcoming regulatory clearances in major markets like the EU and US in H1 2026 represent key catalysts. While the company is still operating at a net loss, the positive trajectory in financial performance and market penetration suggests strong long-term potential for investors willing to accept the inherent risks of a growth-stage medical technology company.

Keywords

Surgical Robotics, Robotic Surgery, SSi Mantra, Medical Devices, Healthcare Technology, Minimally Invasive Surgery, Cardiac Surgery, Telesurgery, AI in Surgery, XR in Surgery, Medical Robotics, SS Innovations International